Piper Sandler Downgrades enGene Therapeutics to Neutral, Lowers Price Target to $4
Benzinga Newsdesk 5 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Piper Sandler analyst Allison Bratzel downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Neutral and lowers the price target from $7 to $4.
Piper Sandler analyst Allison Bratzel downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Neutral and lowers the price target from $7 to $4.